Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

NCT04343989 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT04343989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04343989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2020
Completion date
March 12, 2021
Enrollment
178 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19